SC 13G: Venrock Healthcare Capital Partners III, L.P.
Sentiment: neutral
Topics: sc-13g
AI Summary
SC 13G filing by Venrock Healthcare Capital Partners III, L.P..
Risk Assessment
Risk Level: low
Filing Stats: 4,689 words · 19 min read · ~16 pages · Grade level 9.2 · Accepted 2024-12-04 16:15:14
Key Financial Figures
- $0.0001 — Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class o
Filing Documents
- tm2430061d1_sc13g.htm (SC 13G) — 166KB
- 0001104659-24-125525.txt ( ) — 168KB
From the Filing
SC 13G 1 tm2430061d1_sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Cidara Therapeutics, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 171757206 (CUSIP Number) November 26, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise CUSIP No. 171757206 Page 2 of 17 1. Names of Reporting Persons Venrock Healthcare Capital Partners III, L.P. 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) x (1) (b) ¨ 3. SEC Use Only 4. Citizenship or Place of Organization Delaware Number of Shares Beneficially Owned by Each Reporting Person With 5. Sole Voting Power 0 6. Shared Voting Power 1,129,097 (2) 7. Sole Dispositive Power 0 8. Shared Dispositive Power 1,129,097 (2) 9. Aggregate Amount Beneficially Owned by Each Reporting Person 1,129,097 (2) 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨ 11. Percent of Class Represented by Amount in Row (9) 9.99% (3) 12. Type of Reporting Person (See Instructions) PN (1) Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G. (2) Consists of (i) 132,317 shares of Common Stock and 62,791 shares of Common Stock issuable upon the exercise of pre-funded warrants (the “ Pre-Funded Warrants ”) held by Venrock Healthcare Capital Partners III, L.P.; (ii) 13,247 shares of Common Stock and 6,286 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 620,159 shares of Common Stock and 294,297 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants held by Venrock Healthcare Capital Partners EG, L.P. The Pre-Funded Warrants contain a provision (the “ Beneficial Ownership Blocker ”) which precludes exercise of the Pre-Funded Warrants to the extent that, following exercise, the holder, together with its affiliates and other attribution parties, would own more than 9.99% of the Common Stock outstanding. The share numbers reported above represent the maximum number of shares of Common Stock issuable upon exercise of the Pre-Funded Warrants as a result of the Beneficial Ownership Blocker. (3) This percentage is calculated based upon the sum of: (i) 7,046,633 shares of Common Stock outstanding as of November 4, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “ SEC ”) on November 7, 2024; (ii) 3,892,274 shares of Common Stock issued in the private placement of equity securities by the Issuer that closed on November 26, 2024 (the “ Private Placement ”); and (iii) 363,374 shares issuable upon the exercise of the Pre-Funded Warrants described in Footnote 2 above. CUSIP No. 171757206 Page 3 of 17 1. Names of Reporting Persons VHCP Co-Investment Holdings III, LLC 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) x (1) (b) ¨ 3. SEC Use Only 4. Citizenship or Place of Organization Delaware Number of Shares Beneficially Owned by Each Reporting Person With 5. Sole Voting Power 0 6. Shared Voting Power 1,129,097 (2) 7. Sole Dispositive Power 0 8. Shared Dispositive Power 1,129,097 (2) 9. Aggregate Amount Beneficially Owned by Each Reporting Person 1,129,097 (2) 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨ 11. Percent of Class Represented by Amount in Row (9) 9.99% (3) 12. Type of Reporting Person (See Instructions) OO (1) Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G. (2) Consists of (i) 132,317 shares of Common Stock and 62,791 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants hel